Chengxin Luan

ORCID: 0009-0003-5662-5691
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Biosensors and Analytical Detection
  • Advanced biosensing and bioanalysis techniques
  • Advanced Biosensing Techniques and Applications
  • 3D Printing in Biomedical Research
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Transplantation: Methods and Outcomes
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Chronic Myeloid Leukemia Treatments
  • Photonic Crystals and Applications
  • Mesenchymal stem cell research
  • Multiple Myeloma Research and Treatments
  • Hematological disorders and diagnostics
  • Gold and Silver Nanoparticles Synthesis and Applications
  • RNA Interference and Gene Delivery
  • Biotin and Related Studies
  • Hydrogels: synthesis, properties, applications
  • Bone and Joint Diseases
  • Immune Cell Function and Interaction
  • Electrospun Nanofibers in Biomedical Applications
  • Nanomaterials and Printing Technologies
  • Cancer Cells and Metastasis
  • Immunodeficiency and Autoimmune Disorders
  • HER2/EGFR in Cancer Research

Xinjiang Production and Construction Corps
2024

Anhui Medical University
2020-2023

First Affiliated Hospital of Anhui Medical University
2020-2023

Zhongda Hospital Southeast University
2015-2019

Southeast University
2014-2017

Indiana University School of Medicine
2017

Abstract The development of a highly sensitive platform for multiplex circulating microRNAs (miRNAs) detection is important clinical diagnosis. Here, new type porous hydrogel encapsulated photonic crystal (PhC) barcodes presented with integrated rolling circle amplification (RCA) strategy miRNA quantification. As the surrounding shells PhC are interconnected inverse opal structure hydrophilic scaffolds, they can provide homogeneous water targets reaction and RCA. cores offer stable...

10.1002/adfm.201704458 article EN Advanced Functional Materials 2017-11-23

A core–shell SERS nanotag based VFA with a single test spot for multiplex biomarker detection at pg mL<sup>−1</sup> level wide LDR.

10.1039/c9an00733d article EN The Analyst 2019-01-01

Recovery of circulating tumor cells (CTCs) from cancer patients by an efficient CTCs capture and release method can greatly increase their application in diagnostics treatment cancers. In this paper, we presented a folic acid (FA)-functionalized hybrid photonic barcode for CTCs. The barcodes were formed two nano-ordered parts, poly(ethylene glycol) diacrylate (PEGDA) inverse opal structure sustaining integrity methacrylated gelatin (GelMA) gel filler conjugating FA molecules to mediate cell...

10.1021/acsami.8b06882 article EN ACS Applied Materials & Interfaces 2018-06-08

Abstract Compared with systematic administration such as peripheral intravenous infusion, stem cell therapy by direct injection is theoretically more effective, but some technical barriers low retention rate and engraftment still need to be overcome before its application in humans. Stem supported hydrogel carriers has been increasingly studied recent years. These hydrogels properties similar natural tissues are able fabricate various forms of carriers, which include situ forming hydrogels,...

10.1515/ntrev-2017-0115 article EN Nanotechnology Reviews 2017-03-11

A novel responsive photonic barcode was developed for sensitive multiplex bioassay with fluorescent signal self-amplification.

10.1039/c7nr04867j article EN Nanoscale 2017-01-01

The aim of this retrospective study was to evaluate the efficacy and prognostic factors bortezomib dexamethasone (BD) chemotherapy regimen in treatment newly diagnosed multiple myeloma (MM) patients our hospital.A total 47 MM treated hospital from May 2010 September 2016 were included study. All enrolled received at least two cycles BD regimen.The overall response rate after 68.5% with a complete 23.4%, very good partial 17.0%, 21.3% minor 6.8%. median time survival (OS), progression-free...

10.2147/cmar.s144405 article EN cc-by-nc Cancer Management and Research 2017-08-01

T-cell acute lymphoblastic leukemia (T-ALL) has a poor prognosis as result of severe immunosuppression and rapid tumor progression with resistance to conventional chemotherapy. Excessive IgD may play role in T cell activation via Fc receptor (FcδR). Here we aimed investigate the effects T-ALL demonstrated potential benefit by targeting IgD/FcδR patients IgD-Fc-Ig fusion protein. In patients' blood samples lines, level IgD, percentage FcδR expressing cells binding affinity were determined...

10.1016/j.phrs.2023.106686 article EN cc-by-nc-nd Pharmacological Research 2023-02-04

Tocilizumab is a well-practiced strategy to manage cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy. However, varied efficiency in CRS mitigation by tocilizumab has been reported highlight affecting variables such as tumor types and timing of the administration. The objective this study identify different curative effect between diffuse large B-cell lymphoma (DLBCL) acute lymphoblastic leukemia (ALL) early use for prophylaxis treatment CRS. By...

10.1016/j.bmt.2023.01.002 article EN cc-by-nc-nd Biomedical Technology 2023-03-22

Delayed hematopoietic recovery and increased rate of engraftment failure limit the use umbilical cord blood transplantation (UCBT). We describe a case severe aplastic anemia treated by UCBT combined with mesenchymal stem cells. Our reveals that infusing cells early (about 40 days) after may promote recovery. This experience will guide clinical scientists, especially hematologists, to deal similar situations encourage them widen this strategy.

10.2147/ppa.s81509 article EN cc-by-nc Patient Preference and Adherence 2015-06-01

Gynecomastia refers to the abnormal enlargement of male breast caused by proliferation glandular component breast, typically due sexual hormone disturbance. Multiple medications have been linked development gynecomastia with varying incidences. This adverse event has also associated TKIs such as imatinib, dasatinib, and rarely nilotinib. However, it is poorly described regarded a rare event. Herein, we present first case CML patient who developed after switching from imatinib flumatinib. The...

10.2147/ppa.s481333 article EN cc-by-nc Patient Preference and Adherence 2024-09-01

The hematological manifestations of corona virus disease 2019 (COVID-19) can confound the diagnosis and therapy other diseases. In this paper, we firstly reported a case chronic myeloid leukemia (CML) delayed intolerance to tyrosine kinase inhibitors (TKIs) concurrent with COVID-19.A 56-year-old female was diagnosed as COVID-19 no obvious leukocytosis [white blood cell (WBC), ≤17 × 109/L] or splenomegaly until ablation virus. Bone marrow aspiration conducted establish CML. She accepted an...

10.3389/fonc.2022.921587 article EN cc-by Frontiers in Oncology 2022-06-08
Coming Soon ...